Immunovant Inc (IMVT)

39.02 -0.91 (-2.28%)
Closed USD Disclaimer
39.30 +0.28 (+0.72%)

Immunovant Inc Company Profile

Equity Type
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Contact Information
New York,10018 United States
(917) 580-3099
Top Executives
Peter Salzmann 55 2019 CEO & Director
Andrew J. Fromkin 56 2019 Director
Atul C. Pande 68 2019 Independent Director
Eric Venker 36 2020 Director
Frank M. Torti 44 2019 Executive Chairperson of the Board
George V. Migausky 69 2019 Independent Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.